Skip to content
Homepage
Author:
Skyhawk Therapeutics
Posted Date:
July 14, 2026
Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington’s Disease to the United States, Canada and the United Kingdom
Skyhawk Therapeutics
July 14, 2026
Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease
Skyhawk Therapeutics
June 30, 2026
